tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

IRIngersoll Rand

Industrials · Industrial Machinery · NYSE
Compare with peers → Embed
The 10-K against last year's

96 changes: 16 added, 3 removed, 77 reworded

10-K Feb 17, 2026 vs Feb 19, 2025
Risk FactorsRedline ↓
11.0%
of the text changed · 7,744 words now
12.0%
of the text changed · 8,805 words now
Legal ProceedingsRedline ↓
4.0%
of the text changed · 857 words now
Accounting PoliciesRedline ↓
0.2%
of the text changed · 4,157 words now

10-K 0001628280-26-008617 (2026-02-17) vs 10-K 0001628280-25-006391 (2025-02-19)

The redline

The paragraph that changed most in each section

Marked against last year's 10-K: cut words struck through, new words highlighted and underlined.

Risk Factors 112 words changed in this paragraph; it is 64% similar to last year's version.
We have begun incorporating AI into our business activities and our product and service offerings. As with many innovations, AI presents risks and challenges that could adversely impact our business. The development, adoption, adoption and use of AI technologies are still in their early stages stages, and ineffective or inadequate AI development development, deployment or deployment governance practices could result in unintended consequences. For example, AI algorithms may be flawed or may be based on datasets that are biased or insufficient. In addition, insufficient datasets, and any disruption or failure in the AI functionality we incorporate into our business activities, products or services could adversely impact our business or result in delays or errors in our offerings. Conversely, any failure to successfully develop and deploy AI in our business activities, products and services could adversely affect our competitiveness (particularly if our competitors successfully deploy AI in their businesses, products and services), and the development and deployment of AI will require additional investment and increase our costs. There also may be real or perceived social harm, unfairness, or other outcomes that undermine public confidence in the use and deployment of AI. Any of the foregoing may result in decreased demand for our products or harm to our business, financial statements or reputation.

Source: Item 1A, 10-K 0001628280-26-008617 vs Item 1A, 10-K 0001628280-25-006391

MD&A 100 words changed in this paragraph; it is 32% similar to last year's version.
We can increase the borrowing availability under the New Revolving Credit Facility by up to $1,000.0 Impairment of other intangible assets was $43.7 million in 2025. In the form second quarter of additional commitments on 2025, $36.1 million was recorded to impair a recently acquired indefinite lived tradename within the terms set forth in Precision and Science Technologies segment. In the New Revolving Credit Facility. Our liquidity requirements are significant primarily due fourth quarter of 2025, $7.6 million was recorded to debt service requirements. impair a tradename that was rationalized and rebranded within the Industrial Technologies and Services segment. See Note 12 “Debt” 8 “Goodwill and Other Intangible Assets” to our audited consolidated financial statements included elsewhere in this Form 10-K for further details.

Source: Item 7, 10-K 0001628280-26-008617 vs Item 7, 10-K 0001628280-25-006391

Legal Proceedings 26 words changed in this paragraph; it is 69% similar to last year's version.
from the Company’s asbestos-related litigation. The Company had has an insurance recovery receivable for probable asbestos environmental related recoveries of $157.7 $1.7 million as of December 31, 2023, 2025 which was included in “Other assets” in the Condensed Consolidated Balance Sheets. There were no material recoveries received in the years ended December 31, 2025, 2024 and 2023.

Source: Item 3, via Note 21 – Contingencies, 10-K 0001628280-26-008617 vs Item 3, via Note 22 – Contingencies, 10-K 0001628280-25-006391

Accounting Policies 16 words changed in this paragraph; it is 92% similar to last year's version.
The Company tests intangible assets with indefinite lives annually for impairment and whenever events or changes in circumstances indicate that the carrying value may not be recoverable, using a relief from royalty discounted cash flow fair value model. The quantitative impairment test for indefinite-lived intangible assets involves a comparison of the estimated fair value of the intangible asset with its carrying value. If the carrying value of the intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The relief from royalty method requires the Company to estimate forecasted revenues and determine appropriate discount rates, royalty rates, and terminal growth rates.

Source: Item 8, Note 1 – Summary of Significant Accounting Policies, 10-K 0001628280-26-008617 vs Item 8, Note 1 – Summary of Significant Accounting Policies, 10-K 0001628280-25-006391

Every change, by type

Sentences and paragraphs added, removed or reworded

Sentences and paragraphs of IR's Risk Factors and MD&A, 10-K 2026-02-17 against 10-K 2025-02-19. Each links to the text at sec.gov.

AddedRisk Factors
Russia-Ukraine war and conflicts in the Middle East); shipping products during times of crisis or war; and other factors inherent in foreign operations.

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedRisk Factors
The current U.S. presidential administration has implemented tariffs on imports from various countries, including tariffs on steel and aluminum products under Section 232 of the Trade Expansion Act of 1962, which also apply to certain derivative steel products used in our operations. Some affected countries have announced or imposed reciprocal tariffs on U.S. goods. These measures have contributed to higher costs for certain materials and components. The extent and duration of these tariffs, and their effect on economic conditions and our business, remain uncertain and depend on factors such as legal challenges, negotiations between the U.S. and other countries, potential relief measures, availability and cost of alternative supply sources, and demand for our products in affected markets. Tariffs may increase costs or reduce demand for our products, which could

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedRisk Factors
affect our financial results. In addition, competitors may experience different levels of exposure or have greater ability to mitigate these impacts.

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedRisk Factors
In addition, the successful development and deployment of AI in our business depends on our ability to timely and effectively upskill our existing workforce and attract and retain personnel with AI‑related skills and experience. Competition for AI‑native talent is intense, and if we are unable to develop or recruit the necessary capabilities, we may be unable to fully realize potential efficiency gains, innovation opportunities or competitive advantages from AI, or to respond effectively to AI‑enabled competitive, technological or regulatory developments.

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedRisk Factors
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law by the president of the United States. It includes a broad range of tax reform provisions affecting businesses, including extending and modifying certain key provisions (both U.S. and non-U.S.) of the Tax Cuts & Jobs Act of 2017, and expanding certain Inflation Reduction Act incentives while accelerating the phase-out of others. The impact of the OBBBA is currently reflected on our consolidated financial statements as of December 31, 2025 and we are continuing to assess the impact for future years.

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedRisk Factors
We are also subject to the examination of our tax returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of its provision for taxes. The outcome of such examinations is inherently uncertain. If our effective tax rates were to increase, or if the ultimate determination of our taxes owed is for an amount in excess of amounts

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedMD&A
Years Ended December 31, Percent Change (In millions, except percentages) 2025 2024 2025 vs. 2024 Segment Orders $6,119.6 $5,706.6 7.2% Segment Revenues $6,056.4 $5,818.1 4.1% Segment Adjusted EBITDA $1,747.9 $1,754.8 (0.4)% Segment Adjusted EBITDA Margin 28.9% 30.2 % (130) bps

Read it in 10-K 2026-02-17 at sec.gov ↗

Show the other 8
AddedMD&A
Years Ended December 31, Percent Change (In millions, except percentages) 2025 2024 2025 vs. 2024 Segment Orders $1,596.3 $1,398.9 14.1% Segment Revenues $1,594.5 $1,416.9 12.5% Segment Adjusted EBITDA $478.0 $418.8 14.1% Segment Adjusted EBITDA Margin 30.0% 29.6 % 40 bps

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedMD&A
access, foreign currency translation, and acquisitions. The increase in accounts payable was primarily due to the timing of vendor cash disbursements. The increase in contract liabilities was primarily due to the timing of customer milestone payments for in-process engineered to order contracts.

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedMD&A
(In millions) 2025 2024 Cash flows provided by operating activities $ 1,355.7 $ 1,396.7 Cash flows used in investing activities (660.6) (3,107.7) Cash flows provided by (used in) financing activities (1,053.8) 1,707.5 Free cash flow (1) 1,220.1 1,247.6

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedMD&A
During the second quarter of 2025, certain organizational changes occurred that impacted the composition of all reporting units within our Precision and Science Technologies segment. As a result of these changes, the Company performed an interim goodwill impairment test for all affected reporting units, utilizing a combination of an income and market approach weighted 75% and 25%, respectively, to determine the fair value. In the second quarter of 2025, the Company recognized non-cash impairments of $170.3 million and $59.4 million to reduce the carrying value of goodwill of our Biopharma and Aerospace & Defense reporting units, respectively. Both the Biopharma and Aerospace & Defense reporting units were comprised entirely of businesses acquired in the recent ILC Dover acquisition. After considering the effect of the impairments, the Biopharma and Aerospace & Defense reporting units had goodwill of $816.6 million and $15.9 million, respectively.

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedMD&A
During the second quarter of 2025, due to the reduction in the forecast for Aerospace & Defense and the increase in discount rates, the Company quantitatively tested the relevant indefinite lived tradename for impairment which resulted in a non-cash charge of $36.1 million, within the Precision and Science Technologies segment.

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedMD&A
During the fourth quarter of 2025, the Company retired a tradename and rebranded a business within the Industrial Technologies and Services segment. As a result, the Company recognized an impairment of $7.6 million to reduce the carrying value of the retired tradename.

Read it in 10-K 2026-02-17 at sec.gov ↗

AddedMD&A
We performed our annual impairment test during the fourth quarter and no additional impairments were recorded. Changes in forecasted revenues or any of the other assumptions mentioned above could result in a material non-cash impairment charge in a future period.

Read it in 10-K 2026-02-17 at sec.gov ↗

Next Related parties →